Homology Medicines, Inc., a genetic medicines company, focuses on translating proprietary gene editing and gene therapy technologies into novel treatments for patients with rare diseases. Its proprietary platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs) to deliver genetic medicines in vivo either through a gene therapy or nuclease-free gene editing modality across a range of genetic disorders. The company's various set of AAVHSCs allows company to target, through a single injection, a range of disease-relevant tissues, including the liver, central nervous system, bone marrow, lung, muscle, and eye in gene editing and gene therapy modalities. Its lead product candidate is HMI-102, a gene therapy for the treatment of phenylketonuria (PKU) in adults. The company also develops HMI-103 for the treatment of PKU in pediatric patients; and HMI-202 to treat metachromatic leukodystrophy. Homology Medicines, Inc. was founded in 2015 and is based in Bedford, Massachusetts.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone781-301-7277
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$3.68 million
Profitability
Miscellaneous
Employees124
Next Earnings Date5/13/2019 (Estimated)
OptionableNot Optionable
Homology Medicines (NASDAQ:FIXX) Frequently Asked Questions
What is Homology Medicines' stock symbol?
Homology Medicines trades on the NASDAQ under the ticker symbol "FIXX."
How were Homology Medicines' earnings last quarter?
Homology Medicines Inc (NASDAQ:FIXX) announced its quarterly earnings results on Tuesday, March, 12th. The company reported ($0.51) earnings per share for the quarter, missing the consensus estimate of ($0.44) by $0.07. The business earned $0.98 million during the quarter. Homology Medicines had a negative return on equity of 39.14% and a negative net margin of 1,553.07%. View Homology Medicines' Earnings History.
When is Homology Medicines' next earnings date?
What price target have analysts set for FIXX?
4 equities research analysts have issued 12-month price targets for Homology Medicines' shares. Their forecasts range from $18.50 to $37.00. On average, they anticipate Homology Medicines' stock price to reach $30.1250 in the next year. This suggests a possible upside of 34.7% from the stock's current price. View Analyst Price Targets for Homology Medicines.
What is the consensus analysts' recommendation for Homology Medicines?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Homology Medicines in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Homology Medicines.
Has Homology Medicines been receiving favorable news coverage?
Headlines about FIXX stock have been trending somewhat positive recently, InfoTrie reports. The research firm identifies positive and negative news coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Homology Medicines earned a media sentiment score of 2.0 on InfoTrie's scale. They also gave news stories about the company a news buzz of 2.0 out of 10, indicating that recent news coverage is very unlikely to have an impact on the stock's share price in the next several days.
Are investors shorting Homology Medicines?
Homology Medicines saw a decrease in short interest in the month of April. As of April 15th, there was short interest totalling 1,897,162 shares, a decrease of 26.6% from the March 29th total of 2,583,912 shares. Based on an average daily volume of 549,751 shares, the short-interest ratio is presently 3.5 days. Approximately 9.0% of the shares of the stock are short sold. View Homology Medicines' Current Options Chain.
Who are some of Homology Medicines' key competitors?
Some companies that are related to Homology Medicines include Global Blood Therapeutics (GBT), Amicus Therapeutics (FOLD), Biohaven Pharmaceutical (BHVN), Emergent Biosolutions (EBS), Intercept Pharmaceuticals (ICPT), Ligand Pharmaceuticals (LGND), Akcea Therapeutics (AKCA), Portola Pharmaceuticals (PTLA), Insmed (INSM), Arena Pharmaceuticals (ARNA), Reata Pharmaceuticals (RETA), Mirati Therapeutics (MRTX), The Medicines (MDCO), PTC Therapeutics (PTCT) and Uniqure (QURE).
What other stocks do shareholders of Homology Medicines own?
Who are Homology Medicines' key executives?
Homology Medicines' management team includes the folowing people:
- Dr. Arthur O. Tzianabos, Pres, CEO & Director (Age 56)
- Mr. Timothy P. Kelly, Chief Technical Operations Officer (Age 50)
- Dr. Albert Seymour Ph.D., Chief Scientific Officer (Age 51)
- Dr. Saswati Chatterjee, Co-Founder & Chair of Scientific Advisory Board
- Mr. W. Bradford Smith, CFO, Treasurer & Sec. (Age 63)
When did Homology Medicines IPO?
(FIXX) raised $100 million in an IPO on Wednesday, March 28th 2018. The company issued 6,700,000 shares at $14.00-$16.00 per share. BofA Merrill Lynch, Cowen and Evercore ISI served as the underwriters for the IPO and BTIG was co-manager.
Who are Homology Medicines' major shareholders?
Homology Medicines' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Global Thematic Partners LLC (0.44%) and BNP Paribas Arbitrage SA (0.01%). Company insiders that own Homology Medicines stock include James E Flynn, Kush Parmar, Ventures Iv LP 5Am and Vida Ventures, Llc. View Institutional Ownership Trends for Homology Medicines.
Which major investors are buying Homology Medicines stock?
FIXX stock was bought by a variety of institutional investors in the last quarter, including Global Thematic Partners LLC and BNP Paribas Arbitrage SA. Company insiders that have bought Homology Medicines stock in the last two years include James E Flynn and Vida Ventures, Llc. View Insider Buying and Selling for Homology Medicines.
How do I buy shares of Homology Medicines?
Shares of FIXX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Homology Medicines' stock price today?
One share of FIXX stock can currently be purchased for approximately $22.36.
How big of a company is Homology Medicines?
Homology Medicines has a market capitalization of $839.37 million and generates $3.68 million in revenue each year. The company earns $-57,220,000.00 in net income (profit) each year or ($2.00) on an earnings per share basis. Homology Medicines employs 124 workers across the globe.
What is Homology Medicines' official website?
How can I contact Homology Medicines?
Homology Medicines' mailing address is One Patriots Park, BEDFORD MA, 01730. The company can be reached via phone at 781-301-7277.
MarketBeat Community Rating for Homology Medicines (NASDAQ FIXX)
MarketBeat's community ratings are surveys of what our community members think about Homology Medicines and other stocks. Vote "Outperform" if you believe FIXX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe FIXX will underperform the S&P 500 over the long term. You may vote once every thirty days.
